Palexia Depot (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Depot, is an opioid analgesic presented as a depot formulation for prolonged subcutaneous injection use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate.

GNH USA supplies Palexia Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Palexia Depot is an opioid analgesic that acts on the central nervous system to relieve pain associated with several conditions. - Chronic cancer‑related pain: provides long‑acting relief for patients with persistent tumor‑related pain. - Severe neuropathic pain: helps reduce pain intensity in neuropathic syndromes unresponsive to other opioids. - Post‑surgical pain after major orthopedic procedures: offers extended analgesia when oral opioids are insufficient.

Tapentadol Hydrochloride may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate upset stomach often reported. - Dizziness: transient light‑headedness, especially when standing quickly. - Constipation: reduced bowel motility common with opioid therapy. - Somnolence: feeling unusually sleepy or fatigued. - Headache: mild to moderate cranial pain. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Seizures: rare convulsive episodes, particularly in patients with a seizure history. - Serotonin syndrome: risk when combined with serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - adrenal ​

When using Palexia Depot, clinicians should assess individual risk factors and monitor patients regularly. - Assess renal and hepatic function: adjust therapy if impairment is present. - Evaluate for respiratory depression risk: especially in opioid‑naïve patients. - Review medication history: avoid concurrent use with other central nervous system depressants. - Counsel   - Store at ambient: keep the 

The safety profile ​  

--- ---

---  

t   t  t \